Can a cheaper, easier drug keep CML at bay after stronger treatment?
NCT ID NCT01316250
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether people with chronic myeloid leukemia (CML) who had a good response to the drug nilotinib could switch to imatinib to maintain that response. The goal was to see if imatinib could keep the cancer under control while being easier to take and less expensive. Thirteen newly diagnosed adults participated in this small trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOGENOUS LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
American University of Beirut Medical Center
Beirut, Lebanon
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World check: does bosutinib control CML safely?
- New transplant recipe aims to tame Graft-Versus-Host disease
- Suicide Gene-Equipped t cells aim to make stem cell transplants safer
- New drug combo aims to make stem cell transplants safer for blood cancer patients
- New stem cell method shows promise for young blood cancer patients
- Cord blood transplant offers hope for young blood cancer patients